Hepatocyte growth factor (HGF) binding proteins
View Patent ↗The present invention provides a family of binding proteins that bind and neutralize the activity of hepatocyte growth factor (HGF), in particular human HGF. The binding proteins can be used as diagnostic and/or therapeutic agents. With regard to their therapeutic activity, the binding proteins can be used to treat certain HGF responsive disorders, for example, certain HGF responsive tumors.
1. A method of inhibiting or reducing proliferation of a tumor cell comprising exposing the cell to an effective amount of an isolated antibody that binds human hepatocyte growth factor (HGF) comprising
(i) an immunoglobulin light chain variable region comprising a CDR L1 comprising the amino acid sequence of SEQ ID NO. 18, a CDR L2 comprising the amino acid sequence of SEQ ID NO. 206, and a CDR L3 comprising the amino acid sequence of SEQ ID NO. 20; and
(ii) an immunoglobulin heavy chain variable region comprising a CDR H1 comprising the amino acid sequence of SEQ ID NO. 15, a CDR H2 comprising the amino acid sequence of SEQ ID NO. 205, and a CDR H3 comprising the amino acid sequence of SEQ ID NO. 17; or an antigen binding fragment of the antibody,
to inhibit or reduce proliferation of the tumor cell.
2. A method of inhibiting or reducing tumor growth in a mammal, the method comprising exposing the mammal to an effective amount of an isolated antibody that binds human hepatocyte growth factor (HGF) comprising
(i) an immunoglobulin light chain variable region comprising a CDR L1 comprising the amino acid sequence of SEQ ID NO. 18, a CDR L2 comprising the amino acid sequence of SEQ ID NO. 206, and a CDR L3 comprising the amino acid sequence of SEQ ID NO. 20; and
(ii) an immunoglobulin heavy chain variable region comprising a CDR H1 comprising the amino acid sequence of SEQ ID NO. 15, a CDR H2 comprising the amino acid sequence of SEQ ID NO. 205, and a CDR H3 comprising the amino acid sequence of SEQ ID NO. 17; or an antigen binding fragment of the antibody,
to inhibit or reduce proliferation of the tumor.
3. A method of treating a tumor in a mammal, the method comprising administering to the mammal an effective amount of an isolated antibody that binds human hepatocyte growth factor (HGF) comprising
(i) an immunoglobulin light chain variable region comprising a CDR comprising the amino acid sequence of SEQ ID NO. 18, a CDR L2 comprising the amino acid sequence of SEQ ID NO. 206, and a CDR L3 comprising the amino acid sequence of SEQ ID NO. 20; and
(ii) an immunoglobulin heavy chain variable region comprising a CDR H1 comprising the amino acid sequence of SEQ ID NO. 15, a CDR H2 comprising the amino acid sequence of SEQ ID NO. 205, and a CDR H3 comprising the amino acid sequence of SEQ ID NO. 17, or an antigen binding fragment of the antibody.
4. The method of any one of claims 1 , 2 , or 3 , wherein the Complementarity Determining Region (CDR) sequences are interposed between human or humanized framework sequences.
5. The method of any one of claims 1 , 2 , or 3 , wherein the antibody is a monoclonal antibody.
6. The method of any one of claim 1 , 2 , or 3 , wherein the antibody comprises an immunoglobulin light chain variable region comprising the amino acid sequence of SEQ ID NO. 199, and an immunoglobulin heavy chain variable region comprising the amino acid sequence of SEQ ID NO. 189, or an antigen binding fragment of the antibody.
7. The method of claim 6 , wherein the antibody is a monoclonal antibody.
8. The method of any one of claim 1 , 2 , or 3 , wherein the antibody comprises an immunoglobulin light chain sequence comprising the amino acid sequence of SEQ ID NO. 201, and an immunoglobulin heavy chain sequence comprising the amino acid sequence of SEQ ID NO. 191, or an antigen binding fragment of the antibody.
9. The method of claim 8 , wherein the antibody is a monoclonal antibody.